ADC Development & Differentiation Strategies | Quantitative Systems Pharmacology & MIDD

So at Certara, we support companies, from early discovery all the way to late stage clinical development and post marketing in their drug programs. We offer a whole range of services, but what we are probably most known for is called model informed drug development, or MIDD, where we use modelling and simulation to support discovery and drug development. So I think at the macro level, the big challenge is differentiation. There’s obviously lots of companies working in this space, and really kind of the winners will be the the companies that find a way to differentiate their molecules over others. I think there’s two things that we focus on in specific is the early design. So how do you kind of build confidence that the design of your ADC is going to be differentiated? And secondly, we use modelling and simulation to guide dose selection in the clinic.

So clearly, as this meeting shows, ADCs has become a very popular, area.

It kind of follows a typical pattern that we’ve seen in, you know, checkpoint inhibitors, bispecifics, where after an initial success, people gravitate towards a certain area.

That gives a sense of being part of something bigger and the winning team. But, obviously, at the same time, it differentiation has got to be kind of key because there will only be kind of so much room for kind of, you know, molecules that will be better than others in the marketplace.

So probably three things. So one is clearly we’re seeing a lot of focus on the next generation of ADCs, bispecifics, multi payloads, etcetera. So clearly that offers a lot of potential.

A second area that I’m particularly interested in is using organ on the chip technology as a preclinical model that can predict clinical outcome and safety.

And thirdly, obviously, my own area where we use mechanistic biosimulation called quantitative system pharmacology to guide the design and the translational pharmacology and clinical development of ADCs.

So these meetings are really kind of valuable for us. They are particularly focused, so we like that a lot. They’re focused on a particular area, ADCs, but very much on drug development, which is quite different from other meetings. Know, all we really get out of these meetings is meeting people, networking with key players in the field.

Well, as I said, first of all, it’s wonderful to kind of be at this meeting and meet lots of people in the ADC world. You know, the kind of networking element is is really exciting. And at a personal level, my career started in London. I did my PhD at King’s in in London, so it’s always wonderful to be back in my favorite city in the world.

Okay. Very good. Alright. Yes. Thank you so much.